This topic contains a solution. Click here to go to the answer

Author Question: Which of the following is the result of competing through advertising for a monopolistically ... (Read 47 times)

plus1

  • Hero Member
  • *****
  • Posts: 676
Which of the following is the result of competing through advertising for a monopolistically competitive firm?
 a. Long-run average costs shift downward.
  b. The firm's demand curve become flatter and shifts inward.
  c. The firm's demand curve keeps the same slope and shifts inward.
  d. Long-run average costs shift upward.

Question 2

Implicit costs are best thought of as:
 a. variable costs.
  b. marginal costs.
  c. accounting costs.
  d. opportunity costs.
  e. sunk costs.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

patma1981

  • Sr. Member
  • ****
  • Posts: 292
Answer to Question 1

d

Answer to Question 2

d




plus1

  • Member
  • Posts: 676
Reply 2 on: Jun 30, 2018
Wow, this really help


jomama

  • Member
  • Posts: 346
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

It is important to read food labels and choose foods with low cholesterol and saturated trans fat. You should limit saturated fat to no higher than 6% of daily calories.

Did you know?

Hip fractures are the most serious consequences of osteoporosis. The incidence of hip fractures increases with each decade among patients in their 60s to patients in their 90s for both women and men of all populations. Men and women older than 80 years of age show the highest incidence of hip fractures.

Did you know?

In 1835 it was discovered that a disease of silkworms known as muscardine could be transferred from one silkworm to another, and was caused by a fungus.

Did you know?

Since 1988, the CDC has reported a 99% reduction in bacterial meningitis caused by Haemophilus influenzae, due to the introduction of the vaccine against it.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library